- Company
- Giotrif competitor Vizimpro close to receiving reimbursement
- by Eo, Yun-Ho Sep 15, 2020 06:27am
- Sources report, Pfizer Korea is speeding up the procedure to introduce epidermal growth factor receptor (EGRF) tyrosine kinase inhibitors (TKI) into the market. According to the industry sources, a fifth EPGF TKI Vizimpro (dacomitini) has passed the Health Insurance Assessment and Review Service (HIRA) Cancer Deliberation Committee in la
- Company
- The sales of antiemetic drug Nasea plummeted
- by Kim, Jin-Gu Sep 15, 2020 06:26am
- Sales in the domestic market declined after three types of domestic copyright rights, including the antiemetic drug Nasea (Ramosetron), were transferred from Astellas to Daiichi Sankyo, a Japanese pharmaceutical company. According to IQVIA, a drug research institute, Nasea's sales in the first half of this year were &8361;12.7 billion, d
- Company
- Listed pharma companies financially sound despite COVID-19
- by Kim, Jin-Gu Sep 14, 2020 06:16am
- Apparently, major South Korean pharmaceutical and bio companies have been maintaining the level of financial soundness from late last year for the first half of this year. One of their financial soundness indicators, net liabilities, showed similar level as late last year, which the experts analyze the industry is performing relatively well,
- Company
- Expectations on Zejula are high
- by Sep 14, 2020 06:15am
- “The biggest burden on recurrent ovarian cancer patients is definitely 'relapse'. Zejula can play an important role for patients by preventing recurrence through primary maintenance therapy. In particular, it can be used as an All-comer. The appearance of Zejula is likely to make a big difference in the treatment of ovarian cancer.” Soo
- Company
- Kolmar shareholders agree to dispose CMO and Kolmar Pharma
- by Chon, Seung-Hyun Sep 14, 2020 06:15am
- Kolmar Korea’s shareholders have agreed to dispose of the corporate asset valued at 500 billion won. Kolmar Korea announced the shareholders have deliberated at a general meeting convened on Sept. 10 to pass the agenda of selling the company’s pharmaceutical CMO and Kolmar Pharma to IMM Private Equity (PE). Previously in last May, Kolm
- Company
- The issue is that the NHIS is entitled to indemnity or not
- by Kim, Jin-Gu Sep 14, 2020 06:14am
- A legal dispute has begun between the NHIS and 36 domestic pharmaceutical companies regarding Valsartan's claim for right to indemnity. At the first trial, the issue emerged as an issue whether the NHIS exercises the right to indemnit. The judiciary questioned whether they were eligible to claim from the NHIS, not from patients under the
- Company
- Korean drug industry prepares for Peramiflu generic
- by Kim, Jin-Gu Sep 11, 2020 06:29am
- South Korean pharmaceutical companies are speeding up the launch preparation for a flu drug Peramiflu (peramivir) generic. After filing trials for invalidation of original patent late last year, ten pharmaceutical companies recently applied for the generic approval. If Ministry of Food and Drug Safety (MFDS) approves the generic and the
- Company
- Qurient, expects a big deal for Q203, Q301, Q702, & Q901
- by An, Kyung-Jin Sep 11, 2020 06:28am
- There are high expectations for Qurient to sign a large technology transfer contract in the second half of the year. All four key tasks, including immune anticancer drugs, atopic dermatitis and multi-drug-resistant tuberculosis treatment, are all in the process of discussing technology export, and there is a possibility that at least one contrac
- Company
- Hunterase by GC Pharma is entering the Chinese market
- by Chon, Seung-Hyun Sep 11, 2020 06:28am
- Hunterase by Green Cross is entering the Chinese market GC Pharma announced on the 9th that Hunterase, a treatment for Hunter syndrome, has obtained a license from the NMPA of China. This is the first time that a drug for Hunter syndrome has been approved in China. GC Pharma applied for Hunterase's item license, July of last year in Chi
- Company
- Hanmi to turn efpeglenatide crisis around with new partner
- by An, Kyung-Jin Sep 10, 2020 06:24am
- Hanmi Pharmaceutical’s glucagon-like peptide-1 (GLP-1) agonist ‘efpeglenatide,’ initially licensed out to a global pharmaceutical company Sanofi in 2015, was ultimately returned to the South Korean company. Four months after when the global company indicated its intention to return the rights on the drug May, Sanofi has decided to suspend
